Abstract
We investigated the efficacy of the levodopa on cognitive function in patients with de novo Parkinson’s disease (PD) using the event related potential (ERP) measure and neuropsychological test batteries. We studied 20 PD patients who had never received anti Parkinson medications. After administration of levodopa, the patients revealed significant increase of the achieved categories and decrease of preservation errors in the WSCT, shortening of time in Trail Making Test although MMSE score showed no significant difference. The P3 peak attenuated although there were no differences in peak latency or on scalp topography. These findings suggest that levodopa affect to the neural circuit connect frontal cortex with the striatum and normalize its function, and it causes decrease of P3 peak reflecting appropriate resource allocation. In addition, P3 might be more appropriate indicator rather than psychological test
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
